Efficacy and Safety of Methotrexate, Omalizumab, and Dupilumab for Bullous Pemphigoid in Patients Resistant to Oral Steroids
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study
J Eur Acad Dermatol Venereol 2022 Feb 10;[EPub Ahead of Print], M Velin, PM Dugourd, A Sanchez, P Bahadoran, H Montaudié, T PasseronFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.